Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206857> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4387206857 endingPage "e552" @default.
- W4387206857 startingPage "e551" @default.
- W4387206857 abstract "To report on outcomes, acute toxicities, and the use of dose-escalation with proton therapy (PT) in patients with rhabdomyosarcoma and Ewing sarcoma in a prospective multi-institutional registry (PCG).Data on patients with primary rhabdomyosarcoma and Ewing sarcoma treated with definitive PT (defined as ≥45 Gy) were queried from the PCG registry. A similar query was performed of our institutional database with IRB approval. Overall survival rates were calculated by Kaplan-Meier. Toxicities were scored using CTCAE v4.0.A total of 354 patients across 10 institutions (203 rhabdomyosarcoma, 151 Ewing sarcoma) met the eligibility criteria. Median age was 9 years (Interquartile Range: 5-15). Median dose was 50.4 GyRBE for rhabdomyosarcoma patients (Range: 45-66 GyRBE) and 55.8 GyRBE for Ewing sarcoma patients (Range: 45-66 GyRBE). Median follow-up was 2.4 years (Range 0.3-12.3 years). Two-year overall survival rates were 81.1% (95% CI: 73.7%-88.5%) for rhabdomyosarcoma and 79.1% (95% CI: 71.7%-86.2%) for Ewing sarcoma. The Table lists the prescription doses delivered by tumor histology; 28.1% of rhabdomyosarcoma and 21.9% of Ewing sarcoma patients, respectively, received dose-escalated radiotherapy (defined as >50.4 Gy for rhabdomyosarcoma and >55.8 Gy for Ewing sarcoma). Excluding alopecia and skin desquamation, 153 patients (43.2%) developed any acute grade 2+ non-hematologic toxicity, while 49 patients (13.8%) developed one or more grade 3 toxicities. The most common grade 3 toxicities were anorexia/weight loss (7.3%), pain (7.3%) mucositis/esophagitis (4.8%), and nausea/vomiting (3.1%). One grade 4 toxicity (esophagitis) and no deaths were reported during treatment.In this multi-institutional prospective registry, 28.1% of rhabdomyosarcoma and 21.9% of Ewing sarcoma patients received dose-escalated PT, with 13.8% of patients developing grade 3 toxicities. Long-term outcomes for disease control and late toxicity and anticipated cooperative group trial results are needed to fully assess the benefits and risks of dose-escalated radiotherapy for these tumors." @default.
- W4387206857 created "2023-09-30" @default.
- W4387206857 creator A5001252838 @default.
- W4387206857 creator A5005973513 @default.
- W4387206857 creator A5009839688 @default.
- W4387206857 creator A5009854212 @default.
- W4387206857 creator A5010168970 @default.
- W4387206857 creator A5014115290 @default.
- W4387206857 creator A5020923431 @default.
- W4387206857 creator A5022924056 @default.
- W4387206857 creator A5028634314 @default.
- W4387206857 creator A5029710197 @default.
- W4387206857 creator A5032895490 @default.
- W4387206857 creator A5043792798 @default.
- W4387206857 creator A5046597561 @default.
- W4387206857 creator A5046881923 @default.
- W4387206857 creator A5052573263 @default.
- W4387206857 creator A5055443333 @default.
- W4387206857 creator A5061226372 @default.
- W4387206857 creator A5062492688 @default.
- W4387206857 creator A5067127311 @default.
- W4387206857 creator A5074725191 @default.
- W4387206857 date "2023-10-01" @default.
- W4387206857 modified "2023-10-17" @default.
- W4387206857 title "Multi-Institutional Experience of Proton Therapy for Rhabdomyosarcoma and Ewing Sarcoma in the Proton Collaborative Group (PCG) Prospective Registry" @default.
- W4387206857 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1857" @default.
- W4387206857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785696" @default.
- W4387206857 hasPublicationYear "2023" @default.
- W4387206857 type Work @default.
- W4387206857 citedByCount "0" @default.
- W4387206857 crossrefType "journal-article" @default.
- W4387206857 hasAuthorship W4387206857A5001252838 @default.
- W4387206857 hasAuthorship W4387206857A5005973513 @default.
- W4387206857 hasAuthorship W4387206857A5009839688 @default.
- W4387206857 hasAuthorship W4387206857A5009854212 @default.
- W4387206857 hasAuthorship W4387206857A5010168970 @default.
- W4387206857 hasAuthorship W4387206857A5014115290 @default.
- W4387206857 hasAuthorship W4387206857A5020923431 @default.
- W4387206857 hasAuthorship W4387206857A5022924056 @default.
- W4387206857 hasAuthorship W4387206857A5028634314 @default.
- W4387206857 hasAuthorship W4387206857A5029710197 @default.
- W4387206857 hasAuthorship W4387206857A5032895490 @default.
- W4387206857 hasAuthorship W4387206857A5043792798 @default.
- W4387206857 hasAuthorship W4387206857A5046597561 @default.
- W4387206857 hasAuthorship W4387206857A5046881923 @default.
- W4387206857 hasAuthorship W4387206857A5052573263 @default.
- W4387206857 hasAuthorship W4387206857A5055443333 @default.
- W4387206857 hasAuthorship W4387206857A5061226372 @default.
- W4387206857 hasAuthorship W4387206857A5062492688 @default.
- W4387206857 hasAuthorship W4387206857A5067127311 @default.
- W4387206857 hasAuthorship W4387206857A5074725191 @default.
- W4387206857 hasConcept C119060515 @default.
- W4387206857 hasConcept C126322002 @default.
- W4387206857 hasConcept C141071460 @default.
- W4387206857 hasConcept C142724271 @default.
- W4387206857 hasConcept C143998085 @default.
- W4387206857 hasConcept C2778256501 @default.
- W4387206857 hasConcept C2780844630 @default.
- W4387206857 hasConcept C71924100 @default.
- W4387206857 hasConceptScore W4387206857C119060515 @default.
- W4387206857 hasConceptScore W4387206857C126322002 @default.
- W4387206857 hasConceptScore W4387206857C141071460 @default.
- W4387206857 hasConceptScore W4387206857C142724271 @default.
- W4387206857 hasConceptScore W4387206857C143998085 @default.
- W4387206857 hasConceptScore W4387206857C2778256501 @default.
- W4387206857 hasConceptScore W4387206857C2780844630 @default.
- W4387206857 hasConceptScore W4387206857C71924100 @default.
- W4387206857 hasIssue "2" @default.
- W4387206857 hasLocation W43872068571 @default.
- W4387206857 hasLocation W43872068572 @default.
- W4387206857 hasOpenAccess W4387206857 @default.
- W4387206857 hasPrimaryLocation W43872068571 @default.
- W4387206857 hasRelatedWork W1986439267 @default.
- W4387206857 hasRelatedWork W2003938723 @default.
- W4387206857 hasRelatedWork W2047967234 @default.
- W4387206857 hasRelatedWork W2061253854 @default.
- W4387206857 hasRelatedWork W2118496982 @default.
- W4387206857 hasRelatedWork W2155391523 @default.
- W4387206857 hasRelatedWork W2439875401 @default.
- W4387206857 hasRelatedWork W3162511055 @default.
- W4387206857 hasRelatedWork W4238867864 @default.
- W4387206857 hasRelatedWork W2525756941 @default.
- W4387206857 hasVolume "117" @default.
- W4387206857 isParatext "false" @default.
- W4387206857 isRetracted "false" @default.
- W4387206857 workType "article" @default.